EPISODE #142 Cannabis Legalisation in Germany with Alfredo Pascual, Franziska Katterbach & Tom Blickman
Last month, the recently elected coalition government in Germany announced their initial plans to legalise cannabis for recreational use.
There has understandably been a lot of excitement about this news, so on this week’s episode Alfredo Pascual from Seed Innovations, Franziska Katterbach from Khiron Life Sciences, and Tom Blickman from Transnational Institute join me to discuss how the upcoming legislation may disrupt and revolutionise the recreational and medical markets within Germany and Europe on a wider scale.
About Our Guests
VP of Investment Analysis, Seed Innovations
Based in Germany, Alfredo is a prominent cannabis industry analyst who has been identifying opportunities and generating unique insights for businesses and investors in Europe and Latin America since 2016. He is currently VP of Investment Analysis of Seed Innovations Ltd (LON: SEED), the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space. Before joining Seed Innovations, Alfredo worked as International Analyst at Marijuana Business Daily (MJBiz), the US-based business news and information resource, where he focused on covering how cannabis markets and investments were evolving internationally. Alfredo has an academic background in business and public policy.
Connect with Alfredo on LinkedIn: https://www.linkedin.com/in/alfrep
Senior Project Officer, Transnational Institute
Tom Blickman (1957) is a Senior Project Officer at the Transnational Institute (TNI), based in Amsterdam. Since 1997, he has been working for TNI's Drugs Programme, specializing in international drug control policy and the UN conventions, drug markets, alternative development, money laundering and organised crime. More recently he is closely following cannabis regulation policies in Europe and elsewhere. Tom is a regular speaker at international policy conferences and advises on developments in the drugs field. He is co-editor of the TNI Drug Policy Briefing series.
Connect with Tom on LinkedIn: https://www.linkedin.com/in/tom-blickman-2941a046/
President, Khiron Life Sciences
Franziska Katterbach is an accomplished business executive and legal expert (zugelassene Rechtsanwältin) who brings extensive experience working within Europe's emerging cannabis industry. After completing her legal studies at Universität Leipzig and Landgericht Darmstadt, Franziska joined the corporate law firm Dentons, where she was involved in high-profile deals in the cannabis sector across multiple jurisdictions. Franziska later served as Director of Legal for Canopy's European operations, before joining Khiron. With 8+ years of regulatory expertise and 4+ as business executive in the European emerging cannabis industry, Franziska has well rounded knowledge in the industry. Franziska is considered a pioneer of the medical cannabis market in Germany, working in the medical cannabis industry in Europe on executive level since the very beginning in 2016.
Connect with Franziska on LinkedIn: https://www.linkedin.com/in/franziska-katterbach-438878a9